» Articles » PMID: 35321323

Promising Antioxidative Effect of Berberine in Cardiovascular Diseases

Overview
Journal Front Pharmacol
Date 2022 Mar 24
PMID 35321323
Authors
Affiliations
Soon will be listed here.
Abstract

Berberine (BBR), an important quaternary benzylisoquinoline alkaloid, has been used in Chinese traditional medicine for over 3,000 years. BBR has been shown in both traditional and modern medicine to have a wide range of pharmacological actions, including hypoglycemic, hypolipidemic, anti-obesity, hepatoprotective, anti-inflammatory, and antioxidant activities. The unregulated reaction chain induced by oxidative stress as a crucial mechanism result in myocardial damage, which is involved in the pathogenesis and progression of many cardiovascular diseases (CVDs). Numerous researches have established that BBR protects myocardium and may be beneficial in the treatment of CVDs. Given that the pivotal role of oxidative stress in CVDs, the pharmacological effects of BBR in the treatment and/or management of CVDs have strongly attracted the attention of scholars. Therefore, this review sums up the prevention and treatment mechanisms of BBR in CVDs from , , and finally to the clinical field trials timely. We summarized the antioxidant stress of BBR in the management of coronary atherosclerosis and myocardial ischemia/reperfusion; it also analyzes the pathogenesis of oxidative stress in arrhythmia and heart failure and the therapeutic effects of BBR. In short, BBR is a hopeful drug candidate for the treatment of CVDs, which can intervene in the process of CVDs from multiple angles and different aspects. Therefore, if we want to apply it to the clinic on a large scale, more comprehensive, intensive, and detailed researches are needed to be carried out to clarify the molecular mechanism and targets of BBR.

Citing Articles

Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model.

Lu Y, Mohammad N, Lee J, Aranyos A, Serban K, Brantly M PLoS One. 2024; 19(9):e0310524.

PMID: 39298444 PMC: 11412680. DOI: 10.1371/journal.pone.0310524.


Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.

Nikseresht M, Dabidi Roshan V, Nasiri K Physiol Rep. 2024; 12(15):e16146.

PMID: 39107107 PMC: 11303016. DOI: 10.14814/phy2.16146.


Berberine ameliorates chronic intermittent hypoxia-induced cardiac remodelling by preserving mitochondrial function, role of SIRT6 signalling.

Zhou Z, Zhao Q, Huang Y, Meng S, Chen X, Zhang G J Cell Mol Med. 2024; 28(12):e18407.

PMID: 38894630 PMC: 11187832. DOI: 10.1111/jcmm.18407.


Efficacy and safety of berberine for premature ventricular contractions: a meta-analysis and systematic review of randomized controlled trials.

Qiao M, Lei C, Tan C, Lu C, Chen Z, Zhang Q Pharm Biol. 2023; 61(1):1474-1483.

PMID: 37855412 PMC: 10588516. DOI: 10.1080/13880209.2023.2248167.


Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca homeostasis in a murine model of HFpEF.

Abudureyimu M, Yang M, Wang X, Luo X, Ge J, Peng H Front Med. 2023; 17(6):1219-1235.

PMID: 37656418 DOI: 10.1007/s11684-023-0983-0.


References
1.
Charlton A, Garzarella J, Jandeleit-Dahm K, Jha J . Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. Biology (Basel). 2021; 10(1). PMC: 7830433. DOI: 10.3390/biology10010018. View

2.
Qin-Wei Z, Yong-Guang L . Berberine attenuates myocardial ischemia reperfusion injury by suppressing the activation of PI3K/AKT signaling. Exp Ther Med. 2016; 11(3):978-984. PMC: 4774358. DOI: 10.3892/etm.2016.3018. View

3.
Davidson S, Yellon D, Murphy M, Duchen M . Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res. 2011; 93(3):445-53. DOI: 10.1093/cvr/cvr349. View

4.
Howe C, Lahair M, McCubrey J, Franklin R . Redox regulation of the calcium/calmodulin-dependent protein kinases. J Biol Chem. 2004; 279(43):44573-81. DOI: 10.1074/jbc.M404175200. View

5.
Karam B, Chavez-Moreno A, Koh W, Akar J, Akar F . Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017; 16(1):120. PMC: 5622555. DOI: 10.1186/s12933-017-0604-9. View